Search | Clinical Trials Finder

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 337
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more

Conditions: HIV Infections
Interventions: Adaptavir (monomeric DAPTA); Drug
Lead sponsor: Rapid Laboratories Inc.; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Treatment Resistant Depression
Interventions: NV-5138, matched placebo; Drug
Lead sponsor: Navitor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Adenocarcinoma of Lung, Lung Cancer
Interventions: Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo; Drug · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions: Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: San Diego, California • San Francisco, California • Wilmington, Delaware + 15 more

Conditions: Graft-versus-Host Disease, Stomatitis
Interventions: Thalidomide Gel, Placebo Gel; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Seattle, Washington

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo; Drug · Biological · Other
Lead sponsor: Donald T. Weed, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non Squamous, Non-small-cell Lung Cancer
Interventions: Tivantinib, Placebo, Erlotinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 111
States / cities: Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more

Conditions: Soft Tissue Sarcoma
Interventions: Doxorubicin, APX005M; Drug
Lead sponsor: Alexander Z. Wei, MD; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Duarte, California • St Louis, Missouri • New York, New York

Conditions: Obesity, Insulin Resistance, Insulin Sensitivity, Beta-Cell Dysfunction, Prediabetes
Interventions: Placebo, Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d), High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d); Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Refractory Angina, Chronic Myocardial Ischemia
Interventions: CardiAMP Cell Therapy System, Sham Treatment; Device · Other
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida • Madison, Wisconsin

Conditions: COVID, Corona Virus Infection, COVID19
Interventions: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo; Biological · Other
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more

Conditions: Skin Cancer
Interventions: Electronic + no text message, Electronic monitor + text messages; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Weight Loss
Interventions: Capsinoid, Placebo; Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Aging, Multivitamin and Mineral Supplementation
Interventions: MVM Core Blend, MVM Gold Blend, Placebo; Dietary Supplement
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Gorlin Syndrome
Interventions: Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib; Drug
Lead sponsor: Sol-Gel Technologies, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 24
States / cities: Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more

Conditions: Psychological Trauma
Interventions: Transcranial Magnetic Stimulation (TMS), TMS Sham; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Focus of the Study: Safety of XFB19
Interventions: XFB19, Placebo; Drug
Lead sponsor: Xfibra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Prostate Cancer
Interventions: Dendritic cell immunotherapy; Drug
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Springdale, Arkansas • Los Angeles, California • San Diego, California + 13 more

Conditions: COVID-19, SARS-CoV-2
Interventions: Hydroxychloroquine, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Basal Cell Carcinomas
Interventions: Vismodegib, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

APX005M and Doxorubicin in Advanced Sarcoma

Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

hCT-MSCs for COVID19 ARDS

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

The Effects of Capsinoids on Brown Adipose Tissue Activation in Obesity

Multivitamin and Mineral Supplementation and Healthy Aging

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

The PREVENT Resilience Study

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention